

Franco Franceschini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8942223/publications.pdf>

Version: 2024-02-01

208
papers

6,775
citations

61984

43
h-index

74163

75
g-index

214
all docs

214
docs citations

214
times ranked

8576
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: “Correspondence on “Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome”” by Kawada. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e78-e78.	0.9	9
2	Reproductive Issues and Pregnancy Implications in Systemic Sclerosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 321-342.	6.5	6
3	A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification Systems, and Disease Outcome Measures in Systemic Sclerosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 358-377.	6.5	8
4	Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 412-430.	6.5	23
5	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 295-306.	5.6	78
6	Women of childbearing age living with spondyloarthritis: time for improving knowledge and counselling about reproductive issues. <i>Rheumatology</i> , 2022, 61, 1307-1309.	1.9	2
7	An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 240-250.	6.5	6
8	Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS). <i>Thrombosis and Haemostasis</i> , 2022, 122, 1612-1620.	3.4	0
9	Endothelial Dysfunction in Systemic Lupus Erythematosus and Systemic Sclerosis: A Common Trigger for Different Microvascular Diseases. <i>Frontiers in Medicine</i> , 2022, 9, 849086.	2.6	13
10	Gender differences in primary antiphospholipid syndrome with vascular manifestations in 433 patients from four European centres. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 19-26.	0.8	8
11	CXCL-13 serum levels in patients with rheumatoid arthritis treated with abatacept.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
12	Retention rate of IL-1 inhibitors in Schnitzler's syndrome.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
13	Gender differences in primary antiphospholipid syndrome with vascular manifestations in 433 patients from four European centres.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
14	Rare clinical manifestations in systemic lupus erythematosus: a review on frequency and clinical presentation. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 93-102.	0.8	5
15	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	1.9	7
16	Severe muscle damage with myofiber necrosis and macrophage infiltrates characterize anti-Mi2 positive dermatomyositis. <i>Rheumatology</i> , 2021, 60, 2916-2926.	1.9	13
17	Impact of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Multicenter Cohort Study of 133 Women With Undifferentiated Connective Tissue Disease. <i>Arthritis Care and Research</i> , 2021, 73, 1804-1808.	3.4	7
18	Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part) Tj ETQq0 0 0,rgBT /Overlock 10 T	1.9	8

#	ARTICLE	IF	CITATIONS
19	Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 60, 87-94.	6.5	24
20	Systematic review and meta-analysis of epidemiological studies on the association of occupational exposure to free crystalline silica and systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 81-91.	1.9	9
21	Disease course and obstetric outcomes of pregnancies in juvenile idiopathic arthritis: are there any differences among disease subtypes? A single-centre retrospective study of prospectively followed pregnancies in a dedicated pregnancy clinic. <i>Clinical Rheumatology</i> , 2021, 40, 239-244.	2.2	6
22	Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system. <i>Blood Reviews</i> , 2021, 46, 100745.	5.7	129
23	Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. <i>Journal of Autoimmunity</i> , 2021, 116, 102545.	6.5	25
24	Impact of COVID-19 on outpatient therapy with iloprost for systemic sclerosis digital ulcers. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 109-110.	1.7	3
25	The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. <i>Rheumatology</i> , 2021, 60, 5028-5041.	1.9	34
26	Safety considerations when using drugs in pregnant patients with systemic lupus erythematosus. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 523-536.	2.4	2
27	Real life picture of the use of intravenous immunoglobulins in idiopathic inflammatory myopathies: Results of a multicentric study. <i>Autoimmunity Reviews</i> , 2021, 20, 102757.	5.8	6
28	Systematic Review and Meta-analysis on the Association of Occupational Exposure to Free Crystalline Silica and Rheumatoid Arthritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, , 1.	6.5	11
29	Neutrophil Extracellular Traps in the Autoimmunity Context. <i>Frontiers in Medicine</i> , 2021, 8, 614829.	2.6	25
30	The Influence of Treatment of Inflammatory Arthritis During Pregnancy on the Long-Term Children's Outcome. <i>Frontiers in Pharmacology</i> , 2021, 12, 626258.	3.5	5
31	Baseline characteristics of systemic lupus erythematosus patients included in the Lupus Italian Registry of the Italian Society for Rheumatology. <i>Lupus</i> , 2021, 30, 1233-1243.	1.6	3
32	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg's syndrome). <i>European Respiratory Journal</i> , 2021, 57, 2004158.	6.7	19
33	Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy. <i>Frontiers in Pharmacology</i> , 2021, 12, 666971.	3.5	5
34	Low Preconception Complement Levels Are Associated with Adverse Pregnancy Outcomes in a Multicenter Study of 260 Pregnancies in 197 Women with Antiphospholipid Syndrome or Carriers of Antiphospholipid Antibodies. <i>Biomedicine</i> , 2021, 9, 671.	3.2	17
35	Maternal, pregnancy and neonatal outcomes of twin gestations in women with rheumatic diseases: A single-center, case-control study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 264, 49-55.	1.1	0
36	Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments. <i>Current Pharmaceutical Design</i> , 2021, 27, 4245-4252.	1.9	12

#	ARTICLE	IF	CITATIONS
37	Second Wave Antibodies in Autoimmune Renal Diseases: The Case of Lupus Nephritis. Journal of the American Society of Nephrology: JASN, 2021, 32, 3020-3023.	6.1	6
38	Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis. Rheumatology, 2021, 60, 3176-3188.	1.9	9
39	Novel Targets for Drug Use in Eosinophilic Granulomatosis With Polyangiitis. Frontiers in Medicine, 2021, 8, 754434.	2.6	7
40	Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients's subgroups. Journal of Autoimmunity, 2021, 125, 102744.	6.5	83
41	Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. Clinical and Experimental Rheumatology, 2021, 39, 91-97.	0.8	1
42	Association of anti-RNA polymerase III antibody with silicone breast implants rupture in a multicentre series of Italian patients with systemic sclerosis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 131, 25-28.	0.8	3
43	Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection. Clinical and Experimental Rheumatology, 2021, 39, 695.	0.8	0
44	Reply to: Anti-carbamylated protein antibodies are associated with early abatacept response in rheumatoid arthritis by Castellanos-Moreira et al. Clinical and Experimental Rheumatology, 2021, 39, 1144.	0.8	0
45	Novel Therapies in Takayasu Arteritis. Frontiers in Medicine, 2021, 8, 814075.	2.6	14
46	Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. Clinical and Experimental Rheumatology, 2021, 39, 91-97.	0.8	8
47	Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection. Clinical and Experimental Rheumatology, 2021, 39, 695-695.	0.8	1
48	Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis. Journal of Rheumatology, 2020, 47, 377-386.	2.0	77
49	Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort. Rheumatology, 2020, 59, 2272-2281.	1.9	25
50	Cardiovascular target organ damage in premenopausal systemic lupus erythematosus patients and in controls: Are there any differences?. European Journal of Internal Medicine, 2020, 73, 76-82.	2.2	8
51	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. Journal of Translational Medicine, 2020, 18, 405.	4.4	98
52	Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients. Rheumatology Advances in Practice, 2020, 4, rkaa017.	0.7	15
53	The IMMENSE Study: The Interplay Between iMMune and ENdothelial Cells in Mediating Cardiovascular Risk in Systemic Lupus Erythematosus. Frontiers in Immunology, 2020, 11, 572876.	4.8	11
54	COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. Lancet Rheumatology, The, 2020, 2, e549-e556.	3.9	105

#	ARTICLE	IF	CITATIONS
55	Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1286-1289.	0.9	123
56	P74â€¦Complement variations in systemic lupus erythematosus pregnancies. , 2020, , .		0
57	P75â€¦Anti-SSA/Ro positivity and the risk of congenital heart block: obstetric and fetal outcome in a cohort of anti-SSA/Ro positive pregnant patients with and without autoimmune diseases. , 2020, , .		0
58	P136â€¦SLEDAI response prediction to belimumab therapy by baseline levels of BLyS, APRIL and CD8+ effector memory T-cells. , 2020, , .		0
59	P15â€¦Anti-carbamylated protein antibodiesâ€™ levels are negatively correlated with circulating effector T-cells in a cohort of patients with systemic lupus erythematosus. , 2020, , .		0
60	Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. <i>Frontiers in Immunology</i> , 2020, 11, 584241.	4.8	137
61	P22â€¦Anti-carbamylated protein antibodies in systemic lupus erythematosus: clinical and serological associations. , 2020, , .		0
62	P54â€¦Incidence of skin cancer in systemic lupus erythematosus compared with systemic sclerosis and general population. , 2020, , .		0
63	Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease. <i>Rheumatology</i> , 2020, 59, 1769-1770.	1.9	18
64	Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. <i>Autoimmunity Reviews</i> , 2020, 19, 102568.	5.8	637
65	The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhuri Cure M et al.. <i>Clinical Rheumatology</i> , 2020, 39, 2489-2490.	2.2	11
66	Laboratory considerations amidst the coronavirus disease 2019 outbreak: the Spedali Civili in Brescia experience. <i>Bioanalysis</i> , 2020, 12, 1223-1230.	1.5	8
67	A multicentre study of 244 pregnancies in undifferentiated connective tissue disease: maternal/fetal outcomes and disease evolution. <i>Rheumatology</i> , 2020, 59, 2412-2418.	1.9	19
68	Semiquantitative analysis of line blot assay for myositis-specific and myositis-associated antibodies: a better performance?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e152-e152.	0.9	8
69	FRI0217â€¦SENSITIVITY AND SPECIFICITY OF 2019 DCVAS DRAFT CLASSIFICATION CRITERIA FOR GIANT CELLS ARTERITIS AND TAKAYASU ARTERITIS IN A MONOCENTRIC COHORT OF PATIENTS WITH CLINICAL DIAGNOSIS OF LARGE VESSEL VASCULITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 692.2-692.	0.9	1
70	FRI0480â€¦SCHNITZLERâ€™S SYNDROME: DESCRIPTION OF AN ITALIAN MULTICENTER COHORT. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 837.1-837.	0.9	2
71	Neuropsychiatric Outcome of Children Born to Women With Systemic Lupus Erythematosus and Exposed in Utero to Azathioprine: A Case-Control Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 613239.	3.5	3
72	FRI0239â€¦ANTI-NXP2 ANTIBODIES: CLINICAL AND SEROLOGICAL ASSOCIATIONS IN A MULTICENTRIC ITALIAN STUDY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 703.1-704.	0.9	0

#	ARTICLE	IF	CITATIONS
73	AB0523â€¦TAKAYASU ARTERITIS AND SACROILIITIS: A CASE-CONTROL STUDY. Annals of the Rheumatic Diseases, 2020, 79, 1559.2-1559.	0.9	0
74	AB0678â€¦RISK FACTORS FOR ADVERSE PREGNANCY OUTCOMES IN SPONDYLOARTHRITIS: DISEASE PHENOTYPE AND DISEASE ACTIVITY MAY PLAY A ROLE. Annals of the Rheumatic Diseases, 2020, 79, 1634.1-1634.	0.9	0
75	THU0344â€¦CLINICAL AND HISTOLOGICAL SPECTRUM OF ANTI-MI2 DERMATOMYOSITIS: A MULTICENTRE RETROSPECTIVE COHORT. Annals of the Rheumatic Diseases, 2020, 79, 403-403.	0.9	0
76	SAT0207â€¦ANTI-SSA/RO POSITIVITY AND CONGENITAL HEART BLOCK: OBSTETRIC AND FETAL OUTCOME IN A COHORT OF ANTI-SSA/RO POSITIVE PREGNANT WOMEN WITH AND WITHOUT AUTO-IMMUNE DISEASES FROM THREE ITALIAN TERTIARY REFERRAL CENTERS. Annals of the Rheumatic Diseases, 2020, 79, 1046.1-1047.	0.9	0
77	AB0423â€¦NEUROPSYCHIATRIC OUTCOME OF CHILDREN BORN TO WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) WOMEN AND EXPOSED IN UTERO TO AZATHIOPRINE: A CASE-CONTROL STUDY.. Annals of the Rheumatic Diseases, 2020, 79, 1511.2-1511.	0.9	0
78	AB0624â€¦PREDICTIVE PARAMETERS FOR DEVELOPMENT OF INTERSTITIAL LUNG DISEASE IN IDIOPATHIC INFLAMMATORY MYOSITIS. Annals of the Rheumatic Diseases, 2020, 79, 1607.2-1607.	0.9	0
79	SAT0202â€¦C4 LEVELS AS PREDICTOR OF DISEASE FLARES AND ADVERSE PREGNANCY OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS PREGNANCIES. Annals of the Rheumatic Diseases, 2020, 79, 1043.2-1043.	0.9	0
80	AB0623â€¦RATE AND PREDICTIVE FACTORS ASSOCIATED WITH SUSTAINED REMISSION IN IDIOPATHIC INFLAMMATORY MYOSITIS. Annals of the Rheumatic Diseases, 2020, 79, 1607.1-1607.	0.9	0
81	SAT0368â€¦PREGNANCY IN WOMEN WITH SPONDYLOARTHRITIS: WHO ARE THE PATIENTS AT RISK OF DISEASE FLARE?. Annals of the Rheumatic Diseases, 2020, 79, 1131-1132.	0.9	0
82	AB0522â€¦GENDER DIFFERENCES IN GIANT CELLS ARTERITIS: ANALYSIS OF A MONOCENTRIC COHORT OF 100 PATIENTS.. Annals of the Rheumatic Diseases, 2020, 79, 1558.2-1559.	0.9	0
83	AB0681â€¦COMPARISON BETWEEN DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PREDOMINANT AXIAL VS MAINLY PERIPHERAL SPONDYLOARTHRITIS (SpA) PATIENTS, ENROLLED IN THE ONGOING SIRENA STUDY. Annals of the Rheumatic Diseases, 2020, 79, 1636.1-1636.	0.9	0
84	SAT0328â€¦OUTCOME OF INTERSTITIAL LUNG DISEASE (ILD) IN ANTI-PM/SCL PATIENTS WITH SYSTEMIC SCLEROSIS: RESULTS FROM AN EUSTAR CASE-CONTROL STUDY.. Annals of the Rheumatic Diseases, 2020, 79, 1109.2-1110.	0.9	0
85	FRI0105â€¦EVALUATION OF CXCL13 AND ICAM1 SERUM LEVELS AS PREDICTORS OF CLINICAL RESPONSE TO ABATACEPT IN RHEUMATOID ARTHRITIS.. Annals of the Rheumatic Diseases, 2020, 79, 632.2-632.	0.9	1
86	Autoantibodiesâ€™ titre modulation by anti-BlyS treatment in systemic lupus erythematosus. Lupus, 2019, 28, 1074-1081.	1.6	7
87	Only monospecific anti-DFS70 antibodies aid in the exclusion of antinuclear antibody associated rheumatic diseases: an Italian experience. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1764-1769.	2.3	25
88	Undifferentiated connective tissue disease: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000786.	3.8	28
89	Evaluation of a novel particle-based assay for detection of autoantibodies in idiopathic inflammatory myopathies. Journal of Immunological Methods, 2019, 474, 112661.	1.4	18
90	Diastolic dysfunction in rheumatoid arthritis: a usual travel-mate?. Monaldi Archives for Chest Disease, 2019, 89, .	0.6	4

#	ARTICLE	IF	CITATIONS
91	Pregnancy outcomes in mixed connective tissue disease: a multicentre study. Rheumatology, 2019, 58, 2000-2008.	1.9	10
92	Celiac Disease Prevalence Is Increased in Primary Sjögren's Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study. Journal of Clinical Medicine, 2019, 8, 540.	2.4	20
93	Association Between Changes in BlyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab. Frontiers in Pharmacology, 2019, 10, 433.	3.5	23
94	First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry). Frontiers in Cardiovascular Medicine, 2019, 6, 11.	2.4	39
95	C9orf72 Intermediate Alleles in Patients with Amyotrophic Lateral Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis. NeuroMolecular Medicine, 2019, 21, 150-159.	3.4	19
96	FRI0235â€¦DIFFERENCES BETWEEN MALE AND FEMALE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A SINGLE CENTER EXPERIENCE OVER 20 YEARS OF FOLLOW-UP. , 2019, , .		0
97	AB0481â€¦AUTOANTIBODIESâ€™ TITRE MODULATION BY ANTI-BLYS TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
98	FRI0207â€¦BASELINE LEVELS OF BAFF, APRIL AND CD8+ EFFECTOR MEMORY CELLS AS PREDICTORS OF SLEDAI RESPONSE TO BELIMUMAB THERAPY. , 2019, , .		0
99	FRI0330â€¦MALIGNANCIES IN SYSTEMIC SCLEROSIS PATIENTSWITH ANTI-PM/SCL ANTIBODIES: AN EUSTAR CASE-CONTROL STUDY. , 2019, , .		0
100	AB0668â€¦ASSOCIATION OF ANTI-RNA POLYMERASE III ANTIBODY AND BREAST IMPLANTS RUPTURE IN ITALIAN PATIENTS WITH SYSTEMIC SCLEROSIS. , 2019, , .		1
101	THU0519â€¦DISEASE COURSE AND OUTCOMES OF PREGNANCY IN JUVENIL IDIOPHATIC ARTHRITIS: ANY DIFFERENCE AMONG DISEASE SUBSETS?. , 2019, , .		0
102	AB0512â€¦ANTI-CARBAMYLATED PROTEIN ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS: ARE THEY USEFUL?. , 2019, , .		0
103	AB0955â€¦TRANSITIONAL CARE: A SINGLE CENTER ITALIAN EXPERIENCE. , 2019, , .		0
104	FRI0387â€¦DISEASE COURSE AND OUTCOMES DURING PREGNANCY IN PATIENTS WITH AXIAL SPONDILOARTHRITIS: COMPARISON BETWEEN TNFI USERS AND NAIVE PATIENTS. , 2019, , .		1
105	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. Journal of Clinical Medicine, 2019, 8, 2013.	2.4	118
106	Letter to editor: New onset/recurrence of inflammatory arthralgia/spondyloarthritis in patients treated with vedolizumab for intestinal bowel disease. Clinical Rheumatology, 2019, 38, 609-610.	2.2	6
107	Relationship between endothelial dysfunction, videocapillaroscopy and circulating CD3+CD31+CXCR4+ lymphocytes in systemic lupus erythematosus without cardiovascular risk factors. Lupus, 2019, 28, 210-216.	1.6	17
108	Systemic Lupus Erythematosus and Endothelial Dysfunction: A Close Relationship. Current Rheumatology Reviews, 2019, 15, 177-188.	0.8	27

#	ARTICLE	IF	CITATIONS
109	Update on Antiphospholipid Syndrome: Ten Topics in 2017. <i>Current Rheumatology Reports</i> , 2018, 20, 15.	4.7	22
110	Endothelial Dysfunction in Early Systemic Lupus Erythematosus Patients and Controls Without Previous Cardiovascular Events. <i>Arthritis Care and Research</i> , 2018, 70, 1277-1283.	3.4	21
111	Prevalence and Disease-specific Risk Factors for Lower Urinary Tract Symptoms in Systemic Sclerosis: An International Multicenter Study. <i>Arthritis Care and Research</i> , 2018, 70, 1218-1227.	3.4	7
112	Antinuclear antibodies in Frontotemporal Dementia: the tip's of autoimmunity iceberg?. <i>Journal of Neuroimmunology</i> , 2018, 325, 61-63.	2.3	13
113	The clinico-serological spectrum of overlap myositis. <i>Current Opinion in Rheumatology</i> , 2018, 30, 637-643.	4.3	20
114	Macrophage activation syndrome in adult systemic lupus erythematosus: report of seven adult cases from a single Italian rheumatology center. <i>Reumatismo</i> , 2018, 70, 100-105.	0.9	19
115	Antibodies against antigens related to scleroderma in a cohort of patients with morphea. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 451-458.	0.2	2
116	Timing of onset affects arthritis presentation pattern in antisynthetase syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 44-49.	0.8	30
117	The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 88-98.	6.5	26
118	Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 71-80.	6.5	60
119	Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. <i>Autoimmunity Reviews</i> , 2017, 16, 253-257.	5.8	46
120	Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years. <i>Lupus</i> , 2017, 26, 1197-1204.	1.6	50
121	Anti-topoisomerase-I antibodies in systemic lupus erythematosus and potential association with the presence of anti-dsDNA antibodies. <i>Lupus</i> , 2017, 26, 1121-1122.	1.6	3
122	Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study. <i>Journal of Rheumatology</i> , 2017, 44, 1165-1172.	2.0	51
123	Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures. <i>Immunologic Research</i> , 2017, 65, 150-156.	2.9	27
124	The 2016 classification criteria for primary Sjogren's syndrome: what's new?. <i>BMC Medicine</i> , 2017, 15, 69.	5.5	43
125	The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: an international multicentre study. <i>Rheumatology</i> , 2017, 56, 1874-1883.	1.9	10
126	Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. <i>Clinical Rheumatology</i> , 2017, 36, 469-475.	2.2	45

#	ARTICLE	IF	CITATIONS
127	Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2017, 69, 115-123.	3.4	107
128	Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 303-308.	0.8	16
129	Left ventricular function in rheumatoid arthritis during anti-TNF- α treatment: a speckle tracking prospective echocardiographic study. <i>Monaldi Archives for Chest Disease</i> , 2016, 84, 716.	0.6	13
130	The role of clinically significant antiphospholipid antibodies in systemic lupus erythematosus. <i>Reumatismo</i> , 2016, 68, 137-143.	0.9	14
131	Anti-HMGR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. <i>Autoimmunity Reviews</i> , 2016, 15, 983-993.	5.8	105
132	Serum prealbumin is an independent predictor of mortality in systemic sclerosis outpatients. <i>Rheumatology</i> , 2016, 55, 315-319.	1.9	32
133	Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera. <i>Journal of Immunological Methods</i> , 2016, 433, 1-5.	1.4	109
134	The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus. <i>Lupus</i> , 2016, 25, 1365-1368.	1.6	40
135	Prognostic value of diastolic dysfunction in asymptomatic rheumatoid arthritis patients without cardiovascular risk factors. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 352.	0.8	2
136	Dr. Reggia, <i>et al,</i> reply. <i>Journal of Rheumatology</i> , 2015, 42, 1995.1-1995.	2.0	0
137	Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome. <i>Medicine (United States)</i> , 2015, 94, e1144.	1.0	133
138	Switching from Intravenous to Subcutaneous Formulation of Abatacept: A Single-center Italian Experience on Efficacy and Safety. <i>Journal of Rheumatology</i> , 2015, 42, 193-195.	2.0	15
139	Atteinte cutan�e s��v�re au cours d�une cryoglobulin�mie de type II trait�e efficacement par le thalidomide. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2015, 82, 208-209.	0.0	0
140	Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference. <i>Autoimmunity Reviews</i> , 2015, 14, 692-702.	5.8	63
141	Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2). <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1905-1924.	6.1	58
142	Severe skin involvement in type II cryoglobulinemia successfully treated with thalidomide. <i>Joint Bone Spine</i> , 2015, 82, 130-131.	1.6	4
143	Treatment and functional outcome of patients with cystoid macular edema: a single-center experience. <i>Clinical Rheumatology</i> , 2015, 34, 791-794.	2.2	1
144	Winter lupus flares are associated with low vitamin D levels in a retrospective longitudinal study of Italian adult patients. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 153-8.	0.8	10

#	ARTICLE	IF	CITATIONS
145	Myositis autoantibodies and clinical phenotypes. Autoimmunity Highlights, 2014, 5, 69-75.	3.9	95
146	Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo. Journal of the American Society of Nephrology: JASN, 2014, 25, 2483-2498.	6.1	112
147	Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality. Lupus, 2014, 23, 1255-1258.	1.6	15
148	Evaluation of Ascending Aorta Wall in Rheumatoid Arthritis by Tissue and Strain Doppler Imaging During Anti-“Tumor Necrosis Factor” Therapy. Clinical Cardiology, 2014, 37, 738-743.	1.8	10
149	Centromere Autoantibodies. , 2014, , 179-183.		1
150	In vivo reflectance confocal microscopy features of cutaneous microcirculation and epidermal and dermal changes in diffuse systemic sclerosis and correlation with histological and videocapillaroscopic findings. European Journal of Dermatology, 2014, 24, 349-355.	0.6	9
151	Rare autoantibodies to cellular antigens in systemic lupus erythematosus. Lupus, 2014, 23, 672-677.	1.6	35
152	Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clinical and Experimental Rheumatology, 2014, 32, 891-7.	0.8	66
153	Belimumab for the treatment of refractory systemic lupus erythematosus: real-life experience in the first year of use in 18 Italian patients. Israel Medical Association Journal, 2014, 16, 651-3.	0.1	20
154	Novel aspects of Sjögren’s syndrome in 2012. BMC Medicine, 2013, 11, 93.	5.5	134
155	Antiphospholipid antibodies mediate autoimmunity against dying cells. Autoimmunity, 2013, 46, 302-306.	2.6	24
156	Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic<i>Lupus erythematosus</i>. Autoimmunity, 2013, 46, 363-368.	2.6	33
157	Clinical Significance of IgA Anti-Cardiolipin and IgA Anti-Î2Glycoprotein I Antibodies. Current Rheumatology Reports, 2013, 15, 343.	4.7	53
158	A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies. Clinical and Experimental Rheumatology, 2013, 31, 118-21.	0.8	6
159	Anti-MJ/NXP-2 antibodies are the most common specificity in a cohort of adult caucasian patients with dermatomyositis. Annals of the Rheumatic Diseases, 2012, 71, A49.2-A49.	0.9	1
160	Echocardiographic Evaluation of Asymptomatic Patients Affected by Rheumatoid Arthritis. Journal of Investigative Medicine, 2012, 60, 1204-1208.	1.6	13
161	Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Research and Therapy, 2012, 14, R97.	3.5	124
162	International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis. Arthritis Research and Therapy, 2012, 14, R2.	3.5	19

#	ARTICLE	IF	CITATIONS
163	Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement: a predictive marker for erosive disease?. <i>Reumatismo</i> , 2012, 64, 321-5.	0.9	18
164	Anti-argonaute2 (Ago2/Su) and -Ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS). <i>Autoimmunity</i> , 2011, 44, 90-97.	2.6	15
165	Elastic properties of the ascending aorta in patients with rheumatoid arthritis. <i>International Journal of Cardiology</i> , 2011, 150, 368-369.	1.7	7
166	Autoantibodies to survival of motor neuron complex in patients with polymyositis: Immunoprecipitation of D, E, F, and G proteins without other components of small nuclear ribonucleoproteins. <i>Arthritis and Rheumatism</i> , 2011, 63, 1972-1978.	6.7	40
167	Malignancies in Italian Patients with Systemic Sclerosis Positive for Anti-RNA Polymerase III Antibodies. <i>Journal of Rheumatology</i> , 2011, 38, 1329-1334.	2.0	94
168	Primary Biliary Cirrhosis-related Autoantibodies in a Large Cohort of Italian Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2011, 38, 2180-2185.	2.0	33
169	Cardiological features in idiopathic inflammatory myopathies. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 906-911.	1.5	38
170	Rheumatoid arthritis and diabetes mellitus: Two faces of one coin? Comment on the article by Peters et al. <i>Arthritis Care and Research</i> , 2010, 62, 1201-1202.	3.4	0
171	Anti-RNA Polymerase III Antibodies as a Risk Marker for Early Gastric Antral Vascular Ectasia (GAVE) in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2010, 37, 1544.1-1544.	2.0	31
172	Anti-Th/To Are Common Antinucleolar Autoantibodies in Italian Patients with Scleroderma. <i>Journal of Rheumatology</i> , 2010, 37, 2071-2075.	2.0	52
173	Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. <i>Lupus</i> , 2009, 18, 735-739.	1.6	68
174	Serologic Profile and Mortality Rates of Scleroderma Renal Crisis in Italy. <i>Journal of Rheumatology</i> , 2009, 36, 1464-1469.	2.0	45
175	Anti-RNA polymerase III antibodies: A marker of systemic sclerosis with rapid onset and skin thickening progression. <i>Autoimmunity Reviews</i> , 2009, 8, 580-584.	5.8	46
176	Aortic stiffness and left ventricular hypertrophy in rheumatoid arthritis: Comment on the article by Rudominer et al. <i>Arthritis and Rheumatism</i> , 2009, 60, 2852-2853.	6.7	2
177	Complement Cascade in Systemic Lupus Erythematosus. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 427-434.	3.8	10
178	Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. <i>Autoimmunity Reviews</i> , 2008, 8, 104-106.	5.8	50
179	Hepatitis C virus infection and primary Sjögren's Syndrome: A clinical and serologic description of 9 patients. <i>Autoimmunity Reviews</i> , 2008, 8, 92-94.	5.8	19
180	Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. <i>Lupus</i> , 2008, 17, 727-732.	1.6	58

#	ARTICLE	IF	CITATIONS
181	Autoimmune Polyendocrine Syndromes. , 2008, , 265-269.		2
182	Sjögren's syndrome disease damage index and disease activity index: Scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients. Arthritis and Rheumatism, 2007, 56, 2223-2231.	6.7	167
183	Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clinical Rheumatology, 2005, 24, 48-54.	2.2	101
184	Clinical and serological features of 35 patients with anti-Ki autoantibodies. Lupus, 2005, 14, 837-841.	1.6	10
185	Anti-Ro/SSA and La/SSB antibodies. Autoimmunity, 2005, 38, 55-63.	2.6	204
186	Familial autoimmunity as a risk factor for systemic lupus erythematosus and vice versa: a case-control study. Lupus, 2003, 12, 735-740.	1.6	45
187	Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. Lupus, 2002, 11, 716-721.	1.6	140
188	Pathogenetic associations of maternal Anti-Ro/SSA antibodies. Lupus, 2002, 11, 650-650.	1.6	5
189	Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. British Journal of Rheumatology, 2002, 41, 1357-1366.	2.3	98
190	Diagnostic Tests for Antiribosomal P Protein Antibodies: A Comparative Evaluation of Immunoblotting and ELISA Assays. Journal of Autoimmunity, 2002, 19, 71-77.	6.5	29
191	Systemic Sclerosis Therapy with Iloprost: A Prospective Observational Study of 30 Patients Treated for a Median of 3 Years. Clinical Rheumatology, 2002, 21, 244-250.	2.2	77
192	Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients. Journal of Rheumatology, 2002, 29, 1393-7.	2.0	53
193	Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: A prospective study of 100 women. Arthritis and Rheumatism, 2001, 44, 1832-1835.	6.7	435
194	Clinical and morphological features of kidney involvement in primary Sjögren's syndrome. Nephrology Dialysis Transplantation, 2001, 16, 2328-2336.	0.7	214
195	Chilblain lupus erythematosus is associated with antibodies to SSA/Ro. Lupus, 1999, 8, 215-219.	1.6	49
196	DNA typing of maternal HLA in congenital complete heart block: Comparison with systemic lupus erythematosus and primary Sjögren's syndrome. Arthritis and Rheumatism, 1999, 42, 1757-1764.	6.7	32
197	Antiperinuclear factor in psoriatic arthropathy. Journal of the American Academy of Dermatology, 1999, 40, 910-913.	1.2	4
198	Chilblain Lupus Erythematosus is Associated with Antibodies to SSA/Ro. Advances in Experimental Medicine and Biology, 1999, 455, 167-171.	1.6	12

#	ARTICLE	IF	CITATIONS
199	Determination of antibodies to extractable nuclear antigens by commercial kits: a multicenter study. International Journal of Clinical and Laboratory Research, 1998, 28, 29-33.	1.0	5
200	Transient neonatal bradycardia without heart block associated with anti-Ro antibodies. Lupus, 1997, 6, 487-488.	1.6	21
201	Deforming Arthropathy of the Hands in Systemic Lupus Erythematosus is Associated with Antibodies to SSA/Ro and to SSB/La. Lupus, 1994, 3, 419-422.	1.6	35
202	CD4+ and CD8+ subsets: Naive and memory cells in the peripheral blood of patients with systemic sclerosis. Clinical Rheumatology, 1994, 13, 83-87.	2.2	9
203	Long-term outcome for the mothers of infants with isolated congenital complete heart block: Comment on the article by Julkunen et al. Arthritis and Rheumatism, 1994, 37, 1261-1261.	6.7	3
204	Antinuclear antibodies are not induced by PUVA treatment in patients with uncomplicated psoriasis. Journal of the American Academy of Dermatology, 1994, 30, 955-958.	1.2	11
205	Prevalence, Clinical, and Laboratory Features of Thrombocytopenia Among HIV-Infected Individuals. AIDS Research and Human Retroviruses, 1990, 6, 261-269.	1.1	41
206	Absence of a correlation between T lymphocyte subsets and clinical activity in relapsing-remitting multiple sclerosis. Journal of Neuroimmunology, 1989, 22, 41-45.	2.3	5
207	CXCL-13 serum levels in patients with rheumatoid arthritis treated with abatacept. Clinical and Experimental Rheumatology, 0, , .	0.8	1
208	Retention rate of IL-1 inhibitors in Schnitzler's syndrome. Clinical and Experimental Rheumatology, 0, , .	0.8	3